Novavax shares plunge as company halves revenue forecast on low COVID-19 vaccine demand

Novavax said it now expects 2022 total revenue in the range of $2 billion to $2.3 billion, compared with its prior forecast of $4 billion to $5 billion

from The Hindu - Business